- Home
- COYA
as 12-18-2024 9:48am EST
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 104.3M | IPO Year: | 2022 |
| Target Price: | $16.25 | AVG Volume (30 days): | 70.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.75 - $10.69 | Next Earning Date: | 11-06-2024 |
| Revenue: | $9,554,315 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -39.37% | Revenue Growth (next year): | 87.80% |
Stock Insider Trading Activity of Coya Therapeutics Inc. (COYA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SNYDER DAVID S | COYA | Chief Financial Officer | Nov 14 '24 | Buy | $7.19 | 1,800 | $12,934.44 | 8,800 | |
| Swaminathan Arun | COYA | Chief Executive Officer | Nov 13 '24 | Buy | $7.36 | 5,000 | $36,797.00 | 10,000 | |
| Grossman Fred | COYA | Chief Medical Officer | Nov 11 '24 | Buy | $7.37 | 2,710 | $19,972.70 | 2,710 | |
| Swaminathan Arun | COYA | Chief Executive Officer | Nov 11 '24 | Buy | $7.34 | 5,000 | $36,689.00 | 10,000 |
Latest Coya Therapeutics Inc. News
COYA Breaking Stock News: Dive into COYA Ticker-Specific Updates for Smart Investing
Business Wire
2 hours ago
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
Business Wire
23 days ago
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
Business Wire
a month ago
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Business Wire
a month ago
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
MT Newswires
2 months ago
Coya Therapeutics New CEO Arun Swaminathan Takes Helm
Business Wire
2 months ago
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
TipRanks
2 months ago
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
MT Newswires
2 months ago
Sector Update: Health Care Stocks Ease Late Afternoon
Compare COYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COYA Coya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.